Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma

MA. Ligtenberg, Y. Pico de Coaña, T. Shmushkovich, Y. Yoshimoto, I. Truxova, Y. Yang, M. Betancur-Boissel, AV. Eliseev, AD. Wolfson, R. Kiessling,

. 2018 ; 26 (6) : 1482-1493. [pub] 20180413

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028441

Grantová podpora
R44 HG006788 NHGRI NIH HHS - United States

Adoptive cell therapy (ACT) is becoming a prominent alternative therapeutic treatment for cancer patients relapsing on traditional therapies. In parallel, antibodies targeting immune checkpoint molecules, such as cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) and cell death protein 1 pathway (PD-1), are rapidly being approved for multiple cancer types, including as first line therapy for PD-L1-expressing non-small-cell lung cancer. The combination of ACT and checkpoint blockade could substantially boost the efficacy of ACT. In this study, we generated a novel self-delivering small interfering RNA (siRNA) (sdRNA) that knocked down PD-1 expression on healthy donor T cells as well as patient-derived tumor-infiltrating lymphocytes (TIL). We have developed an alternative chemical modification of RNA backbone for improved stability and increased efficacy. Our results show that T cells treated with sdRNA specific for PD-1 had increased interferon γ (IFN-γ) secreting capacity and that this modality of gene expression interference could be utilized in our rapid expansion protocol for production of TIL for therapy. TIL expanded in the presence of PD-1-specific sdRNA performed with increased functionality against autologous tumor as compared to control TIL. This method of introducing RNAi into T cells to modify the expression of proteins could easily be adopted into any ACT protocol and will lead to the exploration of new combination therapies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028441
003      
CZ-PrNML
005      
20190830114413.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ymthe.2018.04.015 $2 doi
035    __
$a (PubMed)29735366
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ligtenberg, Maarten A $u Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm 17176, Sweden.
245    10
$a Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma / $c MA. Ligtenberg, Y. Pico de Coaña, T. Shmushkovich, Y. Yoshimoto, I. Truxova, Y. Yang, M. Betancur-Boissel, AV. Eliseev, AD. Wolfson, R. Kiessling,
520    9_
$a Adoptive cell therapy (ACT) is becoming a prominent alternative therapeutic treatment for cancer patients relapsing on traditional therapies. In parallel, antibodies targeting immune checkpoint molecules, such as cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) and cell death protein 1 pathway (PD-1), are rapidly being approved for multiple cancer types, including as first line therapy for PD-L1-expressing non-small-cell lung cancer. The combination of ACT and checkpoint blockade could substantially boost the efficacy of ACT. In this study, we generated a novel self-delivering small interfering RNA (siRNA) (sdRNA) that knocked down PD-1 expression on healthy donor T cells as well as patient-derived tumor-infiltrating lymphocytes (TIL). We have developed an alternative chemical modification of RNA backbone for improved stability and increased efficacy. Our results show that T cells treated with sdRNA specific for PD-1 had increased interferon γ (IFN-γ) secreting capacity and that this modality of gene expression interference could be utilized in our rapid expansion protocol for production of TIL for therapy. TIL expanded in the presence of PD-1-specific sdRNA performed with increased functionality against autologous tumor as compared to control TIL. This method of introducing RNAi into T cells to modify the expression of proteins could easily be adopted into any ACT protocol and will lead to the exploration of new combination therapies.
650    _2
$a buněčná a tkáňová terapie $x metody $7 D064987
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a interferon gama $x genetika $x metabolismus $7 D007371
650    _2
$a nádory plic $x imunologie $x metabolismus $x terapie $7 D008175
650    _2
$a melanom $x imunologie $x metabolismus $x terapie $7 D008545
650    _2
$a antigeny CD279 $x genetika $x metabolismus $7 D061026
650    _2
$a RNA interference $x fyziologie $7 D034622
650    _2
$a T-lymfocyty $x metabolismus $7 D013601
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pico de Coaña, Yago $u Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm 17176, Sweden. Electronic address: yagopico@gmail.com.
700    1_
$a Shmushkovich, Taisia $u Advirna LLC, Worcester, MA 01605, USA.
700    1_
$a Yoshimoto, Yuya $u Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm 17176, Sweden; Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi 371-8510, Japan.
700    1_
$a Truxova, Iva $u Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm 17176, Sweden; Charles University, 2(nd) Faculty of Medicine and University Hospital Motol, 150 06 Prague, Czech Republic; Sotio A.S., 170 00 Prague, Czech Republic.
700    1_
$a Yang, Yuan $u Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm 17176, Sweden; Clinical Research Center, Guizhou Medical University Hospital, Guiyang 550025, People's Republic of China.
700    1_
$a Betancur-Boissel, Monica $u Advirna LLC, Worcester, MA 01605, USA.
700    1_
$a Eliseev, Alexey V $u RXi Pharmaceuticals, Marlborough, MA 01752, USA.
700    1_
$a Wolfson, Alexey D $u Advirna LLC, Worcester, MA 01605, USA.
700    1_
$a Kiessling, Rolf $u Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm 17176, Sweden.
773    0_
$w MED00189556 $t Molecular therapy : the journal of the American Society of Gene Therapy $x 1525-0024 $g Roč. 26, č. 6 (2018), s. 1482-1493
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29735366 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190830114738 $b ABA008
999    __
$a ok $b bmc $g 1433590 $s 1066901
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 26 $c 6 $d 1482-1493 $e 20180413 $i 1525-0024 $m Molecular therapy $n Mol Ther $x MED00189556
GRA    __
$a R44 HG006788 $p NHGRI NIH HHS $2 United States
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace